Effects of intravenous furosemide on mucociliary transport and rheological properties of patients under mechanical ventilation by Kondo, Cláudia Seiko  et al.
  Universidade de São Paulo
 
2002
 
Effects of intravenous furosemide on
mucociliary transport and rheological
properties of patients under mechanical
ventilation
 
 
 
http://www.producao.usp.br/handle/BDPI/33211
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Fisioterapia, Fonoaudiologia e Terapia
Ocupacional - FM/MFT
Artigos e Materiais de Revistas Científicas - FM/MFT
Available online http://ccforum.com/content/6/1/081
Research article
Effects of intravenous furosemide on mucociliary transport and
rheological properties of patients under mechanical ventilation
Cláudia Seiko Kondo*†, Mariângela Macchionne*, Naomi Kondo Nakagawa*†, 
Carlos Roberto Ribeiro de Carvalho*, Malcolm King‡, Paulo Hilário Nascimento Saldiva*, 
Geraldo Lorenzi-Filho*
*Universidade de São Paulo, São Paulo, Brazil
†Universidade Federal de São Paulo and Escola Paulista de Medicina, São Paulo, Brazil
‡Pulmonary Research Group, Edmonton, Alberta, Canada
Correspondence: Geraldo Lorenzi-Filho, geraldo.lorenzi@incor.usp.br
Introduction
Although mechanical ventilation (MV) is necessary to improve
ventilatory support in respiratory failure, it is generally known
that this procedure markedly increases the incidence of pul-
monary infection and consequently the morbidity and mortality
of patients. Mucociliary clearance has been reported to be
impaired in patients under MV and this is probably an impor-
tant underlying mechanism in the pathogenesis of pulmonary
infection in these patients [1]. Mucociliary clearance has a
pivotal role in the protection of the respiratory tract against
inhaled noxious agents that are trapped in the blanket of
mucus and transported towards the pharynx by ciliary beating
or coughing. The efficiency of the mucociliary system depends
not only on the integrity of the epithelium and on ciliary activity
but also on the amount of mucus, the depth of the periciliary
layer and the viscoelastic properties of mucus [2].
Airway epithelium is an absorptive and secretory type of
epithelium [3]; the transepithelial movement of electrolytes
generates osmotic gradients that are responsible for the
CA = contact angle; CC = cough clearance; HME = heat and moisture exchanger; IV = intravenous; MCT = mucociliary transport; MV = mechani-
cal ventilation.
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secretion or absorption of water. Pulmonary epithelial ion
transport systems are important in the modulation of the ionic
content and volume of periciliary fluid, which in turn modu-
lates the physical properties and transportability of mucus.
Small changes in the depth of periciliary fluid could greatly
alter the efficiency of interaction between mucus and cilia [4].
Diuretics with an action on ionic channels present in the
airway epithelium can alter ionic movement and change the
physical properties and transportability of mucus. For
instance, inhaling amiloride, a diuretic with action on the
apical Na+ channel, has been reported to increase mucocil-
iary clearance and alter the physical properties of mucus in
patients with cystic fibrosis [5–8].
Intravenous (IV) furosemide is frequently used in patients
under MV with the aim of equilibrating a cumulative positive
fluid balance. However, the possible effects of IV furosemide
on respiratory mucus are largely ignored. Furosemide is a
potent diuretic that acts by inhibiting the NaK(Cl)2 co-trans-
porter in the ascending limb of the loop of Henle. Besides its
renal action, furosemide can also affect epithelial ion trans-
port in the airway. Earlier studies demonstrated that
furosemide inhibits the NaK(Cl)2 co-transporter in canine
airway epithelium [9] and also decreases intracellular Cl–
activity in cultured human airway epithelium [10]. The effects
of inhaled furosemide have also been investigated. Inhaled
furosemide prevents exercise-induced bronchoconstriction in
asthmatic patients [11]. Hasani et al. [12] reported that
inhaled furosemide had no effects on mucociliary clearance in
humans. However, the primary site of furosemide action is the
basolateral membrane of the airway, where it inhibits the
NaK(Cl)2 co-transporter. Therefore the effects of the drug on
the respiratory epithelium might depend on the route of
administration. The aim of the present study was to investi-
gate the effects of IV furosemide on the transportability and
rheological properties of mucus in patients under MV.
Materials and methods
Patients
We studied 26 patients under MV in the Respiratory Intensive
Care Unit of the Pulmonary Division, Hospital das Clínicas,
University of São Paulo. The study was approved by the
Ethics Committee of the University of São Paulo. All patients
were clinically and haemodynamically stable for at least
24 hours before the study. In each of these patients we regis-
tered their clinical data, including arterial pressure, heart rate,
fluid balance, urine output and temperature, during the
24 hours before and during the study. We also registered the
mode of MV, tidal volume, respiratory rate, minute volume,
fraction of inspired oxygen and system of humidification. The
time interval between the initiation of MV and the study was
also recorded.
The patients were distributed in two groups: the furosemide
group consisted of 12 patients (8 female and 4 male) who
received IV furosemide; the control group consisted of 14
patients (3 female and 11 male) who did not receive any
diuretic during the study. Their ages (means ± SD) in the
furosemide and control groups were, respectively, 66 ± 15
years with a range of 30–82 years, and 49 ± 20 years with a
range of 20–76 years. The indication and dose of furosemide
were determined by each patient’s clinical conditions and in
all cases were because of a positive fluid balance. The aim of
including a control group was to make sure that there were
no time-dependent changes in the variables analysed. When
recruiting patients for the control group, our main goal was to
match them in terms of the MV parameters.
Collection of mucus
Respiratory mucus was collected from the endotracheal tube
by sterile technique with a suction catheter. The samples
were extracted from the catheter with a sterile needle and
were immediately immersed in mineral oil to prevent mucus
dehydration. The suction conditions were kept to a minimum
to decrease the degree of shear thinning and the incorpora-
tion of air bubbles [13]. Mucus samples were stored at
–70°C in sealed plastic containers for later analysis.
We collected mucus at 0, 1, 2, 3 and 4 hours. The first
sample (0 hours) in the furosemide group was just before the
administration of the diuretic.
Mucus analysis
Mucus transportability by cilia
Mucociliary transport (MCT) was determined in vitro in the
frog palate preparation, which possesses an epithelium that
is similar to that in the upper airways in humans [14]. All
animals were cared for in compliance with the Guide for Care
and Use of Laboratory Animals published by the National
Institutes of Health (NIH publication 85-23, revised 1985). To
deplete the palate mucus, the palate was stored for 2 days at
4°C in a humidified chamber covered with plastic wrap [15].
Ciliary activity is maintained under these experimental condi-
tions. The frog mucus was collected and used as a control for
measurements of transport rate. Measurements of transport
rate were determined with a stereomicroscope (Zeiss)
equipped with a reticulated eyepiece. We timed the displace-
ment of the mucus samples across a segment between the
anterior and posterior parts of the palate. During the experi-
ments the palate was kept at ambient temperature (20–25°C)
and 100% humidity, provided by ultrasonic nebulization
[13,16]. The results were expressed as relative transport
velocity and corresponded to the ratio of velocity of the test
mucus sample to that of the control frog mucus.
Contact angle (CA)
Respiratory mucus is a complex material that possesses both
rheological properties, which are directly involved in the trans-
portability of mucus, and physical properties such as wettabil-
ity, which is an important property in the interaction between
the mucus and the respiratory epithelial surface. Wettability is
the tendency of a biological fluid to spread when deposited
on a solid plane surface owing to the interaction between the
surface and the molecules of the mucus. The degree of wet-
tability is determined by the contact angle between the
tangent to the liquid–air interface and the horizontal at the
triple point where the three phases meet [17].
CA was determined by an eyepiece that had a goniometer
with a scale of 0° to 180°. Mucus samples were placed on a
plate pretreated with sulphochromic acid to remove electrical
charges, which interfered with measurements. During the
experiments a water bath kept at 37°C allowed humidification
to prevent the dehydration of mucus [13,16].
Mucus transportability by cough
Cough clearance (CC) experiments were performed in vitro in
a simulated cough machine adapted from King et al. [18]. This
machine consisted of a cylinder of compressed air serving as
gas supply, a solenoid valve that controlled the release of gas,
and a cylindrical acrylic tube 4 mm in internal diameter and
133 mm in length as a model trachea. Mucus was introduced
into the tube and connected to the simulated cough machine.
The solenoid valve released the air for 0.5 s under a pressure
of 280 kPa. Clearance was quantified by determining the dis-
placement of mucus in millimetres [13,16].
Rheological properties
The rheological properties of mucus samples were deter-
mined in the present study with a magnetic microrheometer
as described by King and Macklem [19] and modified by Sil-
veira et al. [20]. The microrheometer measured the displace-
ment, resulting from a sinusoidal oscillating magnetic field, of
a small steel ball inserted in the mucus sample. The motion of
the ball was opposed by viscous and elastic forces.
The plexiglass container with the drop of mucus sample and
the steel ball was placed into the gap of a magnetic toroid
that was mounted on the stage of a projecting microscope
and driven by a sine-wave generator. The shadow of the ball
was projected onto two photocells that captured its oscilla-
tory movement and provided an electrical output in proportion
to the displacement of the moving ball. The toroid current and
the output of the photocells were transmitted to a digital
oscilloscope connected to an IBM-compatible personal com-
puter for storage and off-line processing [13,16].
Measurements were made at two different frequencies:
1 radian/s (ciliary movement) and 100 radians/s (cough) [21].
Two parameters were obtained: first, the relation between
stress and strain, representing the overall impedance of the
mucus (G*), and second, the phase lag between stress and
strain, representing the ratio between viscosity and elasticity
(tan δ).
Statistical analysis
Statistical analysis was performed by profile analysis [13],
which takes into account time correlation between different
sampling times (0, 1, 2, 3 and 4 hours). This is a multivariate
method in which only one statistical model is applied. This
method considers the group along the time and basic
hypotheses can be tested enabling post hoc corrections to
be performed through contrasts so as to identify, or discrimi-
nate, significant differences. Basic hypotheses are the follow-
ing: H01, in which there is no interaction between the factors
group and time (parallelism); H02, in which there is no differ-
ence between the use of either control or furosemide group
(coincidence); and H03, in which there is no time effect.
When H01 was accepted, hypotheses H02 and H03 were
tested. When H01 was rejected, hypotheses H02 and H03
were not tested and post hoc corrections for multiple com-
parisons were performed through contrasts.
P < 0.05 was considered statistically significant.
Results
Demographic and MV parameters are described in Tables 1
and 2. The time lag between the initiation of MV and the
study was 9 ± 6 and 9 ± 6 days for the furosemide and
control groups, respectively (P = 0.9). In the furosemide
group, two patients were using the heat and moisture
exchanger (HME), and 10 were using the heated humidifier.
In the control group, six patients were using the HME and
eight were using the heated humidifier.
The results of mucus transportability in the frog palate (MCT)
and cough (CC) are presented in Figs 1 and 2, respectively.
MCT decreased significantly after furosemide administration
and did not recover to baseline values by 4 hours
(P = 0.0001). In contrast, MCT remained constant in the
control group (Fig. 1). There was a trend that did not reach
statistical significance for a decrease in CC in the furosemide
group (Fig. 2).
The results of the remaining parameters, contact angle, log G*
and tan δ measured at 1 and 100 radians/s, are presented in
Table 3. There were no significant differences between groups.
Discussion
To our knowledge this is the first study to investigate the
effects of IV furosemide on mucus transportability in vitro and
the physical properties of mucus from patients under MV. Our
results suggest that IV furosemide might acutely impair MCT
for up to 4 hours after administration.
The mucociliary escalator of the lungs is an important protec-
tive transport system by means of which inhaled particles and
microorganisms are removed from the tracheobronchial
system. Lung mucociliary clearance is influenced by several
factors, including the integrity of the ciliated epithelium and
the thickness and physical properties of the periciliary or
mucous layer [12]. Under normal circumstances, active ion
transport in the respiratory epithelium is important in the pro-
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duction and regulation of the volume and composition of the
respiratory tract secretion, which in turn is important for ade-
quate mucociliary interaction [22]. Pharmacological interfer-
ence in ionic transport is caused by a new class of drugs that
can change MCT. For instance, inhalation of amiloride
increases MCT in patients with cystic fibrosis by inhibiting the
active absorption of salt and water from airway surfaces
[23,24].
The effects of furosemide on the respiratory epithelium have
attracted interest in the decade since Bianco et al. [11]
reported that inhaled furosemide prevents exercise-induced
bronchoconstriction in asthmatic patients. The mechanism of
this protective effect remains to be established. The effects of
inhaled furosemide on mucociliary clearance have been
investigated and the results are controversial. Hasani et al.
[12] reported that nebulized furosemide does not affect
mucociliary clearance measured with a radioaerosol tech-
nique in healthy and asthmatic subjects. It must be stressed
that the primary site of furosemide action is the basolateral
membrane of the airway, where it inhibits the NaK(Cl)2 co-
transporter. Inhaled furosemide might therefore not reach the
basolateral membrane of airway epithelial cells in vivo
[11,25]. In fact, experimental studies have demonstrated that,
in contrast with the serosal application of furosemide,
mucosal application has no effect on co-transporter function
[26]. Winters and Yeates [27] have reported an increase in
lung mucociliary clearance in vivo after the inhalation of
aerosolized furosemide and the IV administration of
furosemide in dogs and baboons. However, in this study the
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Table 1
Demographic characteristics and mechanical ventilation parameters of the control group
Fluid balance (ml) Diuresis (ml)
FiO2 VE Vasoactive Tracheal 
Sex Age Diagnosis Mode (%) (L/min) drugs secretion 24 hours Study 24 hours Study
F 70 Mediastinal tumor resection AMV 40 11.7 – S. viridans +31 +233 1150 75
M 20 Head trauma VAPS 45 9.6 – P. aeruginosa +78 –10 2350 400
M 20 Head trauma VAPS 40 9.2 – P. aeruginosa +341 +83 2450 400
S. aureus
M 63 Cerebrovascular accident, 
heart failure, osteomyelitis VAPS 46 10.5 Dobutamine A. calcoaceticus –1310 –154 3180 480
P. aeruginosa
S. aureus
M 47 Lung neoplasm SIMV 40 9.7 Dobutamine – +564 +321 1920 120
M 76 Lung neoplasm, pneumonia AMV 36 8.7 Dobutamine P. aeruginosa +1408 +132 780 100
Dopamine X. maltophilia
M 66 Heart failure, pneumonia, PC 50 8.7 Dobutamine A. calcoaceticus +534 +373 2300 120
pulmonar lobectomy
M 22 Craniotomy, pneumonia AMV 40 9.4 – A. calcoaceticus +1411 +171 2400 140
E. cloacae
M 41 Hyperosmolar coma, PC/SIMV 40 10.7 – A. baumanii –518 +86 550 150
cerebrovascular accident S. viridans
S. coagulase neg
M 61 Lung neoplasm, COPD, 
acute renal insufficiency PS 45 11.7 Dobutamine S. marcescens +1871 +183 60 20
A. baumanii
X. maltophilia
F 58 Drug intoxication, PC/SIMV 40 7.7 – S. aureus +286 –98 2000 171
pneumonia
M 74 Pulmonary tumor resection AMV 30 8.3 – – –462 +133 1650 125
M 51 Respiratory failure PC/SIMV 40 10.5 Noradrenaline – +1452 –59 2000 720
F 23 Thyroidectomy SIMV 40 5.0 – – +3551 +290 2570 200
Mean 50 40 9.4 671 82 1824 258
±SD ±20 ±4 ±1.7 ±1169 ±212 ±847 ±218
Abbreviations: AMV, assisted mechanical ventilation; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; PC,
pressure-controlled ventilation; PS, pressure-support ventilation; SIMV, synchronized intermittent mandatory ventilation; VAPS, volume-assured
pressure support, VE, minute volume. *P < 0.05.
properties and in vitro transportability of mucus were not
determined.
In our study we observed a decrease in MCT after
furosemide administration that did not recover to the baseline
by 4 hours. Furosemide inhibits the NaK(Cl)2 co-transporter,
which is one of the physiological mechanisms involved in the
respiratory hydration of mucus; its inhibition could therefore
interfere in the rheological properties of mucus [4,28]. The
ionic concentration of Na+ and Cl2– in mucus can also influ-
ence the rheology and transportability of mucus indepen-
dently of its total water content [6,29]. In addition, diuresis
might lead to systemic dehydration and impairment of
mucociliary clearance [30,31]. In our study, furosemide
administration was a clinical decision based on cumulative
positive fluid balance and determined by the medical staff.
Interestingly, the furosemide and control groups had similar
fluid balance in the 24 hours before the onset of the study. As
expected, furosemide promoted increased diuresis. It must
be stressed that in our study the patients were not monitored
invasively. Fluid balance, diureses and haemodynamic status
can give only gross estimates of fluid balance. In summary,
from this study it is not possible to determine the mechanism
involved in the effects of furosemide on MCT.
The mode of humidification was not uniform between the
groups. Nakagawa et al. [13] have recently compared the
effects of two systems of humidification (HME with a Pall BB
100 F, and a heated humidifier) on respiratory mucus and its
transportability in patients under MV. The effects were evalu-
ated for up to 72 hours of MV. They observed a decrease in
CC in the HME group only after 72 hours of MV. Because
the present study was limited to an intervention in a short
period (4 hours), baseline clinical conditions, including age,
MV parameters and the mode of humidification, probably did
not influence the results. Indeed, our control group showed
no time-dependent changes in all parameters studied. Infec-
tion also affects respiratory mucous and epithelium.
However, the occurrence of pulmonary infection was similar
in both groups (10 patients in the control group and 9 in the
furosemide group), suggesting that this factor did not influ-
ence our results.
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Table 2
Demographic characteristics and mechanical ventilation parameters of furosemide group
Fluid balance (ml) Diuresis (ml)
FiO2 VE Vasoactive Tracheal 
Sex Age Diagnosis Mode (%) (L/min) drugs secretion 24 hours Study 24 hours Study
F 61 Pneumonia VAPS 45 7.5 – X. maltophilia +380 –15 2600 500
F 64 Acute renal failure CMV 45 6.9 Noradrenaline S. aureus +768 +178 482 275
Dopamine X. maltophilia
M 66 Pulmonar lobectomy, SIMV 40 8.6 Dobutamine P. aeruginosa +1175 –200 1580 540
respiratory failure A. calcoaceticus
M 30 Wound of gunshot injury SIMV 30 4.7 – – +960 –1475 1250 1800
F 86 Burn PC 40 4.2 Dobutamine – –610 –366 3400 860
F 59 Penetrating thorax wound CPAP 40 5.8 – – –740 –734 1750 890
F 82 Pneumonia AMV 50 8.6 – A. calcoaceticus +1242 +264 1440 300
F 82 Pneumonia AC 45 9.5 – A. calcoaceticus +418 +192 1120 540
F 67 Sjogren syndrome CMV 40 8.7 – P. aeruginosa +502 +604 1850 200
M 74 Wegener’s granulomatosis, VAPS 40 12 Dopamine P. maltophilia +1988 –1194 1670 1700
pneumonia Dobutamine
M 61 COPD, respiratory failure PC 60 9.9 Dopamine S. marcescens +2244 –1 290 100
A. baumanii
X. maltophilia
F 63 Cerebrovascular accident, AC 55 8.9 Dobutamine A. calcoaceticus +2190 –22 1460 440
PE, pneumonia
Mean 66.2 44 8.3 813 –231 1575 679
±SD ±14.7 ±8 ±2.1 ±1036 ±616 ±836 ±554
P 0.03* 0.20 0.17 0.64 0.19 0.23 0.01*
Abbreviations: AC, assist/control ventilation; AMV, assisted mechanical ventilation; CMV, controlled mechanical ventilation; COPD, chronic
obstructive pulmonary disease; FiO2, fraction of inspired oxygen; PC, pressure-controlled ventilation; PE, pulmonary embolism; SIMV, synchronized
intermittent mandatory ventilation; CPAP, continuous positive airway pressure; VAPS, volume-assured pressure support, VE, minute volume.
*P < 0.05.
In our study, impairment in MCT was not matched with signifi-
cant changes in other physical properties of mucus. It is possi-
ble that MCT is a more sensitive method for detecting
mucociliary impairment. Because our study involved a relatively
small number of patients, we cannot discard a type 2 error to
explain the absence of furosemide effect on other mucus para-
meters. An alternative explanation is that furosemide has direct
effects on the ciliary beating frequency of the frog palate.
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Table 3
Mucus analysis (means ± SD)
MCT (relative speed) CA (degrees) CC (mm) logG*, 1 radian/s
Time (hours) C F C F C F C F
0 0.83 ± 0.22 1.01* ± 0.21 44.14 ± 8.78 37.75 ± 8.13 58.21 ± 30 74.25 ± 29.46 1.66 ± 0.38 1.45 ± 0.43
1 0.88 ± 0.24 0.81 ± 0.16 45.43 ± 8.53 41.25 ± 10.9 60.43 ± 29 62.5 ± 29.44 1.49 ± 0.44 1.57 ± 0.49
2 0.85 ± 0.21 0.77 ± 0.2 44.93 ± 8.11 40.92 ± 7.8 63.6 ± 37.44 46.92 ± 28.6 1.62 ± 0.35 1.55 ± 0.42
3 0.88 ± 0.2 0.82 ± 0.22 45 ± 10.2 41.75 ± 9 57.6 ± 34.25 63.1 ± 28.93 1.37 ± 0.57 1.61 ± 0.38
4 0.88 ± 0.18 0.82 ± 0.2 44.29 ± 6.29 39.92 ± 11.4 60.57 ± 26.57 57.75 ± 31.22 1.46 ± 0.4 1.48 ± 0.27
P 0.88 0.0001* 0.25 0.54 0.60
logG*, 100 radians/s tanδ , 1 radian/s tanδ , 100 radians/s
Time (hours) C F C F C F
0 1.65 ± 0.24 1.61 ± 0.42 0.51 ± 0.12 0.51 ± 0.19 0.73 ± 0.22 0.84 ± 0.41
1 1.68 ± 0.3 1.71 ± 0.38 0.57 ± 0.14 0.54 ± 0.25 0.75 ± 0.23 0.79 ± 0.34
2 1.67 ± 0.35 1.69 ± 0.26 0.49 ± 0.13 0.61 ± 0.26 0.86 ± 0.27 0.78 ± 0.26
3 1.40 ± 0.36 1.71 ± 0.32 0.47 ± 0.15 0.63 ± 0.36 0.63 ± 0.17 0.72 ± 0.16
4 1.51 ± 0.23 1.62 ± 0.25 0.6 ± 0.15 0.57 ± 0.14 0.66 ± 0.22 0.82 ± 0.39
P 0.16 0.16 0.14
Abbreviations: C, control group; CA, contact angle; CC, cough clearance; F, furosemide group; MCT, mucociliary transport. *P < 0.05.
Figure 1
Results of mucociliary transport in vitro in frog palate. There was a
significant decrease in MCT after furosemide administration that did
not recover to the baseline by 4 hours. * P < 0.05.
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Figure 2
Results of mucus transportability by cough measured with a simulated
cough machine. The results are shown in terms of relative change in
CC (CC at 1, 2, 3 and 4 hours divided by CC at time 0, i.e. before
drug administration).
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In conclusion, our preliminary results support the hypothesis
that IV furosemide might acutely impair mucociliary clearance.
In patients with respiratory failure and MV, many factors can
potentially impair MCT, such as ventilation with a high con-
centration of oxygen, the activation of inflammatory mediator
systems, colonization by bacteria, suction-induced lesions of
the mucous membrane, infections and drugs [1]. The mecha-
nisms and the clinical relevance of our findings remain to be
established.
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